Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

27.68 -0.85 (-2.98%)
Streaming Delayed Price Updated: 2:03 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Via ACCESS Newswire
News headline image
1 Value Stock on Our Watchlist and 2 We Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Topics Retirement
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Stocks Under $50 with Warning Signs
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session after a Bank of America analyst lowered the firm's price target on the shares and reports... 
Via StockStory
News headline image
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead
Amphastar Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.5%. The stock now trades at $27.76, marking a 31% gain. This was partly due to... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Profitable Stock Worth Your Attention and 2 Facing Headwinds
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered into an exclusive license agreement with Nanjing... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Via ACCESS Newswire
News headline image
3 Low-Volatility Stocks We Find Risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Via ACCESS Newswire
News headline image
Amphastar Director Sells 16,679 Shares for $441,800 ↗
Amphastar is down big in 2025, but recently announced positive FDA-related news. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
Amphastar Announces FDA Approval for Teriparatide Injection
Via ACCESS Newswire
News headline image
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential... 
Via StockStory
Topics Economy
News headline image
Amphastar (AMPH) Q3 2025 Earnings Call Transcript ↗
Amphastar (AMPH) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
Via ACCESS Newswire
News headline image
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was... 
Via StockStory
Topics Earnings
News headline image
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESS Newswire
News headline image
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.